MAY 20, 2020 11:45 AM EDT | APAC MAY 21, 2020 2:45 PM CST

Lung Cancer Gene Fusion Assays using NanoString® nCounter® Technology

Speaker
  • Thoracic Oncology Consultant, Hospital Clínic de Barcelona
    Biography
      Dr. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart gained a PhD focusing on molecular lung cancer biology at the Molecular Biology Laboratory at Hospital Germans Trias i Pujol, Barcelona and the General Thoracic Surgery and Oncology Laboratory, at the University of California San Francisco (UCSF). She has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching. Most recently Dr. Reguart has been designated the lead of the Thoracic Oncology Unit at the Hospital Clínic.
      Throughout her career, Dr. Reguart has shown her interest in addressing lung cancer. She has been involved in the design and patient recruitment to many personalized lung cancer trials. In addition to clinical practice and patient care, she also conducts basic research with a special interest in lung cancer biomarkers and the identification of predictors of therapy response at the Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory in August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona. She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations.
      Dr. Reguart is an active member of several international organizations including the Lung Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC). She is a member of the Board of Directors of the Spanish Lung Cancer Group (SLCG) since 2007, and is the author of over 80 scientific publications with an H-Score of 38.

    Abstract

    Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine genomic testing of several druggable oncogenic biomarkers—EGFR, ALK, ROS1, and BRAF—in new metastatic non-squamous NSCLC patients, while a number of other emerging molecular targets, such as RET and NTRK gene rearrangements, MET exon 14 skipping mutations (METex14), and activating HER2 or KRAS mutations are likely approaching clinical practice. Consequently, more extensive analysis such as multiplexed DNA/RNA profiling platforms are increasingly required for comprehensive biomarker testing of lung cancer. We validated the sensitivity of the NanoString® nCounter® technology to identify driver mutations (METex14) and gene fusions (ALK, ROS1, RET1, NTRK) in lung cancer patients. Our work demonstrates that embedding two DNA and RNA (using the nCounter) multiplexing technologies early into the routine workup of patients with advanced NSCLC is feasible and useful to identify distinct subsets of patients amenable to targeted therapies, resulting in significantly improved outcomes.

    Research Use Only. Not for use in Diagnostic Procedures.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources